Genmab A/S 2023 Annual Report with Sustainability Disclosures
Company: Genmab A/S
Sector: Professional & technical services
Country: Denmark
Year: 2023
Type: Annual Report with Sustainability Disclosures
Pages: 138
The report highlights Genmab's 2023 commercial expansion, including TALVEY becoming its eighth approved medicine. Consolidated revenue reached DKK 16,474 million, while the report also disclosed 2023 Scope 1 and Scope 2 emissions of 317 and 238 tCO2e. The climate section states that the 2022 footprint served as the baseline for Genmab's climate target.
Data Services
From bulk PDFs to structured indicators and machine-readable documents.